Drug intelligence / Profile preview

QL1706

Development stage: Phase 4
Lead developer: Qilu Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

QL1706 is an investigational bifunctional monoclonal antibody that combines the activities of both PD-1 and CTLA-4 antibodies. It is designed to enhance immune responses against cancer cells by blocking these immune checkpoints. QL1706 has shown promising antitumor activity in various solid tumors, including non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC), and cervical cancer (CC).

Other names: tuvorilimab

Targets

PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on QL1706.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL1706.

Explore the full profile